Pharmaceutical Technology
SEPTEMBER 8, 2022
Speciality pharmacies play a crucial role in medication dosing, disease and side effects management, and patient care. The post Leading speciality pharmacies in pharma appeared first on Pharmaceutical Technology. Value-based delivery models encourage providers to target costs, quality, and health outcomes.
MedCity News
NOVEMBER 21, 2022
Merck is acquiring Imago BioSciences, a clinical-stage biotech whose lead drug is in development for myelofibrosis and other blood cancers. The deal gives the pharmaceutical giant a small molecule that could provide an alternative to a class of drugs that introduce dangerous side effects.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JULY 1, 2022
billion buyout of Principia Biopharma has run into trouble, after the FDA placed it on partial clinical hold while a safety signal is investigated. All the BTK inhibitors are designed to be able to cross the blood brain barrier and enter the central nervous system, dampening down the autoimmune response that leads to neuronal damage in MS.
pharmaphorum
SEPTEMBER 7, 2022
Good’s lead drug is due to start clinical testing next year. Foremost among those was Bristol-Myers Squibb and Nektar’s bempegaldesleukin, a pegylated form of recombinant IL-2 that aimed to extend the half-life of the cytokine in the body, extending the time between doses, and simultaneously reducing side effects.
pharmaphorum
OCTOBER 27, 2022
The Swiss biotech is seeking a priority review for vamorolone, which was licensed from US biotech ReveraGen BioPharma in 2020 after Santhera its former DMD therapy candidate idebenone failed clinical testing and was abandoned. Its lead drug has already claimed fast track and rare paediatric disease designations from the FDA.
PM360
JULY 13, 2023
Our lead indications are HER2-positive metastatic breast cancer (mBC) and metastatic castration-resistant prostate cancer (mCRPC). Our clinical data is encouraging and supports potential registrational paths based upon its molecular design focused upon selectivity for cancer-relevant T cells and decreased side effects.
European Pharmaceutical Review
JULY 20, 2023
In June 2023, an array of leading voices in AAV development for cell and gene therapies articulated the current challenges and their optimism for the rapidly advancing sector at the Cell and Gene Therapy Summit event in London. For cell and gene therapy, a “big issue” she stated, was the complexity of manufacturing.
Expert insights. Personalized for you.
45 
Let's personalize your content